Evidence map›Paper›PMID 27913964›Full record

ArticleNeurotoxicity research2017

Intracerebroventricular Streptozotocin as a Model of Alzheimer's Disease: Neurochemical and Behavioral Characterization in Mice.

Katherine Garcia Ravelli, Barbara Dos Anjos Rosário, Rosana Camarini, Marina Sorrentino Hernandes, Luiz Roberto Britto

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 130 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer's disease through CB1 activation and inflammation modulation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Katherine Garcia RavelliDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Av. Professor Lineu Prestes, CEP 05508-900, Sao Paulo, 1524, Brazil.
Barbara Dos Anjos RosárioDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Av. Professor Lineu Prestes, CEP 05508-900, Sao Paulo, 1524, Brazil.
Rosana CamariniDepartment of Pharmacology, University of Sao Paulo, Sao Paulo, Brazil.
Marina Sorrentino HernandesDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Av. Professor Lineu Prestes, CEP 05508-900, Sao Paulo, 1524, Brazil. marinash@icb.usp.br.
Luiz Roberto BrittoDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Av. Professor Lineu Prestes, CEP 05508-900, Sao Paulo, 1524, Brazil.
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptozotocin has been widely used to mimic some aspects of Alzheimer's disease (AD). However, especially in mice, several characteristics involved in the streptozotocin (STZ)-induced AD pathology are not well known. The main purpose of this study was to evaluate temporally the expression of AD-related proteins, such as amyloid-β (Aβ), choline acetyltransferase (ChAT), synapsin, axonal neurofilaments, and phosphorylated Tau in the hippocampus following intracerebroventricular (icv) administration of STZ in adult mice. We also analyzed the impact of STZ on short- and long-term memory by novel object recognition test. Male mice were injected with STZ or citrate buffer, and AD-related proteins were evaluated by immunoblotting assays in the hippocampus at 7, 14, or 21 days after injection. No differences between the groups were found at 7 days. The majority of AD markers evaluated were found altered at 14 days, i.e., the STZ group showed increased amyloid-β protein and neurofilament expression, increased phosphorylation of Tau protein, and decreased synapsin expression levels compared to controls. Except for synapsin, all of these neurochemical changes were transient and did not last up to 21 days of STZ injection. Moreover, both short-term and long-term memory deficits were demonstrated after STZ treatment at 14 and 21 days after STZ treatment.

Indexed as

StreptozocinAlzheimer DiseaseAmyloid beta-PeptidesAnimalsCholine O-AcetyltransferaseDisease Models, AnimalHippocampusInfusions, IntraventricularIntermediate FilamentsMaleMemory DisordersMicePhosphorylationRecognition, PsychologySynapsinstau ProteinsAmyloid beta-PeptidesCholine O-AcetyltransferaseStreptozocinSynapsinstau ProteinsAlzheimer diseaseAmyloid βNeurofilamentsStreptozotocinSynapsinTau protein

Identifiers

PMID27913964
OpenAlexW2557887080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.